CADRx Precision Medicines

CADRx Precision Medicines CADRx Precision Medicines CADRx Precision Medicines

CADRx Precision Medicines

CADRx Precision Medicines CADRx Precision Medicines CADRx Precision Medicines
  • Home
  • About
  • Publications and IP
  • Physicians & Researchers
    • Clinical
    • Scientific
  • Leadership
  • Contact Us
  • More
    • Home
    • About
    • Publications and IP
    • Physicians & Researchers
      • Clinical
      • Scientific
    • Leadership
    • Contact Us
  • Home
  • About
  • Publications and IP
  • Physicians & Researchers
    • Clinical
    • Scientific
  • Leadership
  • Contact Us

Proof of Concept: Synergy

Synergy- mycophenolic acid (MPA) in combination with oxaliplatin (OXP)-dysplastic oral KERATINOCYTES

Synergy- mycophenolic acid (MPA) in combination with oxaliplatin (OXP)-dysplastic oral KERATINOCYTES

Synergy- mycophenolic acid (MPA) in combination with oxaliplatin (OXP)-dysplastic oral KERATINOCYTES

 IC50 values.  Note the striking synergy in keratinocytes, indicating potency against early and low grade lesions and an indication for the watchful waiting population. 

 Liu X, Liang D, Tsai R. 2022 Small 

Synergy- mycophenolic acid (MPA) in combination with oxaliplatin (OXP)-oral squamous cell CARCINOMA

Synergy- mycophenolic acid (MPA) in combination with oxaliplatin (OXP)-dysplastic oral KERATINOCYTES

Synergy- mycophenolic acid (MPA) in combination with oxaliplatin (OXP)-dysplastic oral KERATINOCYTES

  

IC50 values. Synergy in oral squamous carcinoma cells, indicating potency against oral cancer for a cancer treatment and neoadjuvant therapy indication.

Liu X, Liang D, Tsai R. 2022 Small 

Proof of Concept: Histopathological lesion reversal

Product specifications

    Copyright © 2023 CADRx Precision Medicines - All Rights Reserved.

    This website uses cookies.

    We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

    Accept